Regulatory Approval

A state-funded grant unites UCLA and industry to create a scientific benchmark for cannabis flavors, aiming to enhance public safety and regulatory clarity.

A life-changing treatment for a rare kidney disease is now easily accessible in France, ending a long wait for patients and bolstering a French pharma firm.

The oil & gas operator is one step from a NYSE listing, promising a 13.5% dividend yield and a major consolidation play in the mature assets market.

Corcept Therapeutics' stock plummeted and it now faces legal probes after the FDA rejected its key drug, revealing the company was warned not to apply.

Promising Phase 2 data for a potential first-in-class neuropathic corneal pain therapy to be showcased, offering new hope for a debilitating condition.

A new community survey names 2026's top privacy apps, from browsers to messaging, while revealing deep user anxiety over AI's impact on personal data.

With backing from a top hospital, VolitionRx seeks reimbursement for its Nu.Q® blood test, aiming to transform lung cancer care in France and beyond.

After a regulatory setback, Ultragenyx has resubmitted its BLA for UX111, a potential first-ever treatment for the devastating Sanfilippo syndrome type A.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

Lexicon Pharmaceuticals raised nearly $95 million to fund its drug pipeline, but the move sent its stock plunging as investors weighed future promise against immediate dilution.

Quetzal Therapeutics’ oral capsule for a rare leukemia could replace grueling IVs. The FDA's Fast Track status signals a major shift for patients and investors.

A novel, dissolvable microsphere for chronic pain gets the green light in Canada, paving the way for a North American market entry and a new era in pain management.

A landmark study validates Panakeia's AI, which provides critical cancer biomarker results in minutes, promising to revolutionize patient care globally.

A new platform in REGA's sandbox lets Saudi investors buy property shares, making real estate investment more accessible, transparent, and secure.

The FDA has qualified MolecuLightDX's measurement tool, a move set to standardize clinical trials, accelerate innovation, and redefine wound healing.

The Spanish pharma giant secures approval for the first oral antibiotic specifically for acne in China, targeting a multi-billion dollar dermatology market.

Projected to surpass $3.2 billion by 2032, the skin booster market is booming. Discover the science, business, and societal shifts driving this trend.

A new medical device enters real-world trials, promising to solve a critical failure point in dialysis grafts and improve life for millions of patients.

Finnish firm GlucoModicum publishes research validating its needle-free tech, a major step toward ending painful finger pricks for diabetes management.

Bullion International Group's major acquisition of SOLIT Group reshapes Europe's market, creating a $2.1B entity. What does this mean for investors?